Treatment of chemotherapy-induced anemia

Japanese Journal of Cancer and Chemotherapy

Volumn 41, Issue 4, 2014, Pages 416-420

  Kadokura, Genmu ^a   Katsumata, Noriyuki ^a  

^a NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

Author keywords

Anemia in cancer patients; Erythropoiesis stimulating agents (ESAs); Transfusion

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; ERYTHROCYTE TRANSFUSION; HUMAN; PROGNOSIS; VENOUS THROMBOEMBOLISM;

EID: 84903139593     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Caro JJ, Salas M, Ward A, et al: Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91 (12): 2214-2221, 2001. (Pubitemid 32552805)
2. Motzer RJ, Mazumdar M, Bacik J, et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8): 2530-2540, 1999. (Pubitemid 29368255)
3. Hasenclever D and Diehl V: A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339(21): 1506-1514, 1998.
4. http://www.jcog.jp/doctor/tool/ctcaev4.html
5. Drew RE: Hematologic consequences of malignancy: anemia and bleeding. UpToDate: 2013.
6. Delsol G, Guiu-Godfrin B, Guiu M, et al: Leukoerythroblastosis and cancer frequency, prognosis, and physiopathologic significance. Cancer 44(3): 1009-1013, 1979. (Pubitemid 10242235)
7. Shamdas GJ, Ahmann FR, Matzner MB, et al: Leukoerythroblastic anemia in metastatic prostate cancer. Clinical and prognostic significance in patients with hormone-refractory disease. Cancer 71(11): 3594-3600, 1993. (Pubitemid 23152670)
8. Means RT Jr and Krantz SB: Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80(7): 1639-1647, 1992.
9. Spira MA and Lynch EC: Autoimmune hemolytic anemia and carcinoma: an unusual association. Am J Med 67(5): 753-758, 1979. (Pubitemid 10218825)
10. Weiss RB, Freiman J, Kweder SL, et al: Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 16(5): 1885-1889, 1998. (Pubitemid 28234736)
11. Sheldon R and Slaughter D: A syndrome of microangiopathic hemolytic anemia, renal impairment and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. Cancer 58(7): 1428-1436, 1986. (Pubitemid 16016824)
12. Lesesne JB, Rothschild N, Erickson B, et al: Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 7(6): 781-789, 1989. (Pubitemid 19145601)
13. Jackson AM, Rose BD, Graff LG, et al: Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 101(1): 41-44, 1984. (Pubitemid 14088065)
14. Rizzo JD, Brouwers M, Hurley P, et al: American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28(33): 4996-5010, 2010.
15. Grant MD, Piper M, Bohlius J, et al: Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update. Comparative Effectiveness Review Number 113, Agency for Healthcare Research and Quality, United States of America, 2013. http:// effectivehealthcare.ahrq.gov/ehc/products/170/1480/cancer-anemia-treatment- report-130425.pdf
16. Tonia T, Mettler A, Robert N, et al: Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 12: CD003407, 2012.
17. Acs G, Acs P, Beckwith SM, et al: Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61(9): 3561-3565, 2001. (Pubitemid 32694960)
18. Aapro M, Jelkmann W, Constantinescu SN, et al: Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer 106(7): 1249-1258, 2012.
19. Ohashi Y, Uemura Y, Fujisaka Y, et al: Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: individual patient data from Japanese randomized, placebo-controlled trials. Cancer Sci 104(4): 481-485, 2013.
20. Schrier SL, Steensma DP and Loprinzi CL: Role of erythropoiesis- stimulating agents in the treatment of anemia in patients with cancer. UpToDate: 2013.
21. Wu WC, Rathore SS, Wang Y, et al: Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 345(17): 1230-1236, 2001. (Pubitemid 34951486)
22. Hébert PC, Wells G, Blajchman M A, et al: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 340 (6): 409-417, 1999. (Pubitemid 29084771)
23. Villanueva C, Colomo A, Bosch A, et al: Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 368(1): 11-21, 2013.
24. Khorana AA, Francis CW, Blumberg N, et al: Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 168(21): 2377-2381, 2008.